| abstract |
the invention relates to an anti-cd16a antigen-binding protein for use in nk cell-based immunotherapy, wherein the anti-cd16a antigen-binding protein must be administered intermittently, and in combination with a cytokine. in certain embodiments, the antigen-binding protein is a tetravalent and bispecific tandem cd30 / cd16a diabody. |